Markets:

Overview

News

Currencies

International

Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

52.21 -4.06 (-7.22%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >

Rosen Law Firm Urges GeneDx Holdings Corp. (NASDAQ: WGS) Stockholders to Contact the Firm for Information About Their Rights

June 05, 2026

From Rosen Law Firm

Via Business Wire

WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm

June 05, 2026

From The Schall Law Firm

Via Business Wire

Investor Notice: Robbins LLP Informs Investors of the GeneDx Holdings Corp. Class Action Lawsuit

June 04, 2026

From Robbins LLP

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Deadline on August 3, 2026

June 04, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

From GeneDx

Via Business Wire

Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm

May 19, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 18, 2026

From Kirby McInerney LLP

Via GlobeNewswire

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 13, 2026

From Kirby McInerney LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

May 12, 2026

From Pomerantz LLP

Via GlobeNewswire

WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

May 11, 2026

From Kirby McInerney LLP

Via GlobeNewswire

GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

May 09, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

GENEDX HOLDINGS CORP. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

May 06, 2026

From Kirby McInerney LLP

Via Business Wire

Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

May 06, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

GeneDx Holdings Corp. (WGS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

May 06, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

May 05, 2026

From Law Offices of Frank R. Cruz

Via Business Wire

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

May 04, 2026

From GeneDx

Via Business Wire

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

April 13, 2026

From GeneDx

Via Business Wire

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

March 11, 2026

From GeneDx

Via Business Wire

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

March 10, 2026

From GeneDx

Via Business Wire

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

March 09, 2026

From GeneDx

Via Business Wire

GeneDx to Participate in Upcoming Investor Conferences

February 25, 2026

From GeneDx

Via Business Wire

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

February 23, 2026

From GeneDx

Via Business Wire

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

February 11, 2026

From GeneDx

Via Business Wire

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

February 03, 2026

From GeneDx

Via Business Wire

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026

From Halper Sadeh LLC

Via Business Wire

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

January 12, 2026

From GeneDx

Via Business Wire

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

January 08, 2026

From GeneDx

Via Business Wire

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

January 07, 2026

From GeneDx

Via Business Wire

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

January 06, 2026

From GeneDx

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.